Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oral hexavalent reassortant rotavirus live attenuated vaccine
- Development stage
- Unknown
- Lead developer
- Wuhan Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Oral hexavalent reassortant rotavirus live attenuated vaccine (Vero cell), marketed under the trade names Rotasiro and Wusheng Erlunbao, is a live-attenuated vaccine developed by the Wuhan Institute of Biological Products (a subsidiary of China National Biotec Group/Sinopharm) for the prevention of rotavirus gastroenteritis in infants. The vaccine is constructed on the backbone of the bovine rotavirus UK Compton strain (G6P[5]) and incorporates reassorted human VP7 gene fragments to cover six major rotavirus serotypes: G1, G2, G3, G4, G8, and G9. It was approved by China's National Medical Products Administration (NMPA) in August 2025 for infants aged 6 to 36 weeks, offering a broader spectrum of protection compared to existing pentavalent vaccines by uniquely including the G8 and G9 serotypes.
- Brand names
- RotasiroWusheng Erlunbao武生儿轮宝
- Other names
- Hexavalent reassortant rotavirus vaccineReassortant rotavirus vaccine, live, oral, hexavalent (Vero cell)口服六价重配轮状病毒减毒活疫苗口服六价重配轮状病毒减毒活疫苗（Vero细胞）
02
Targets
VP4 (Rotavirus VP4)VP6 (Rotavirus capsid protein VP6)VP7 (Rotavirus VP7)
Beyond the preview
Go deeper on oral hexavalent reassortant rotavirus live attenuated vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oral hexavalent reassortant rotavirus live attenuated vaccine.